Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease

Krackhardt, Florian; Waliszewski, Matthias; Kočka, Viktor; Toušek, Petr; Janek, Bronislav; Hudec, Martin; Lozano, Fernando; Roman, Koldobika Garcia-San; Blanco, Bruno García del; Mauri, Josepa; Heang, Tay Mok; Ahn, Tae Hoon; Jeong, Myung Ho; Herberger, Denny; Tomulić, Vjekoslav; Lévy, G.; Sebagh, Laurent; Rischner, Jérôme; Pansiéri, Michel

doi:10.1007/s10557-021-07290-z

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using clopidogrel rather than ticagrelor had no effect on MACE, bleeding, and thrombotic events in stable CAD or ACS patients [ 16 , 17 ]. As observed in our study, compared with 6 months of DAPT, 3–6 months of DAPT did not increase the risk of cardiovascular death, myocardial infarction, target vessel revascularization (TVR), definite and probable stent thrombosis, and Bleeding Academic Research Consortium (BARC) 1 year after PF-SES implantation [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease

Landolff,

Quillot,

Picard

et al. 2023

Journal of Interventional Cardiology

Self Cite

View full text Add to dashboard Cite

Objectives. The aim of this postmarket clinical study was to assess the safety and efficacy of the latest generation polymer-free sirolimus-eluting stents (PF-SES) in an all-comers population comparing outcomes in stable coronary artery disease (CAD) versus acute coronary syndrome (ACS) in France. Background. The efficacy and safety of the first-generation PF-SES have already been demonstrated by randomized controlled trials and “all-comers” observational studies. Methods. For this all-comers observational, prospective, multicenter study, 1456 patients were recruited in 22 French centers. The primary endpoint was target lesion revascularization (TLR) rate at 12 months and secondary endpoints included major adverse cardiac events (MACE) and bleeding. Results. 895 patients had stable CAD and 561 had ACS. At 12 months, 2% of patients had a TLR, with similar rates between stable CAD and ACS (1.9% vs 2.2%, p = 0.7). The overall MACE rate was 5.2% with an expected higher rate in patients with ACS as compared to those with stable CAD (7.3% vs 3.9%, p = 0.007). The overall bleeding event rate was 4.5%, with similar rates in stable CAD as compared to ACS patients (3.8% vs 5.6%, p = 0.3). Dual antiplatelet therapy (DAPT) interruptions prior to the recommended duration occurred in 41.7% of patients with no increase in MACE rates as compared to patients who did not prematurely interrupt DAPT (3.9% vs 6.1%, p = 0.073). Conclusions. The latest generation PF-SES is associated with low clinical event rates in these all-comers patients. There was a high rate of prematurely terminated DAPT, without any effect on MACE at 12 months. This trial is registered with NCT03809715.

show abstract

Section: Discussionmentioning

confidence: 99%

In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease

Landolff,

Quillot,

Picard

et al. 2023

Journal of Interventional Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The emphasis of treatment for AMI is prompt myocardial reperfusion, including the application of thrombolytic therapy or primary percutaneous coronary intervention (PCI) (2). Antithrombotic (anticoagulant or antiplatelet) effects are important mechanisms of PCI, which can reduce even prevent perioperative and long-term ischemic cardiovascular events, including stent thrombosis and recurrent myocardial infarction (3,4). Substantial progress has been made in myocardial infarction treatment, such as early reperfusion therapy, which has extensively decreased the mortality rate in patients with AMI (5).…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and risk factors of in-hospital gastrointestinal bleeding in patients with acute myocardial infarction

Zhong

Quan²,

Dang³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundGastrointestinal bleeding (GIB) is one of the most serious complications of acute myocardial infarction (AMI) and is correlated with poor outcomes.ObjectiveTo evaluate the prevalence, risk factors and in-hospital mortality of GIB in patients with AMI.MethodsThis observational case-control study retrospectively enrolled consecutive patients with AMI from the Department of Cardiovascular Medicine and Cardiovascular Surgery of the First Affiliated Hospital of Xi'an Jiaotong University from January 2015 to December 2020. GIB after AMI was identified by International Classification of Diseases (ICD) codes from inpatient medical settings and validated by medical record review. AMI patients without GIB were accordingly classified as the control group. Propensity score matching (PSM) was used to match with the GIB group and the control group. All anonymized clinical data were provided by the Biobank of the First Affiliated Hospital of Xi'an Jiaotong University.ResultsA total of 5,868 AMI patients were enrolled, 0.87% (51/5,868) of whom developed GIB after AMI. On the univariate analysis, history of diabetes, chronic kidney disease, Killip IV, a lower hemoglobin concentration, a higher serum level of creatinine, blood urea nitrogen and D-dimer were closely associated with the risk of GIB (P < 0.05). On the multivariable analysis, a lower hemoglobin concentration (OR: 0.93, 95% CI: 0.89–0.96, P < 0.001) was independently associated with the risk of GIB. Patients with GIB had a much higher in-hospital mortality rate than those without GIB (14.3 vs. 2.1%, P = 0.047). In-hospital mortality among patients with GIB after AMI appeared to be associated with a decreased hemoglobin concentration (OR: 0.93, 95% CI: 0.86–0.99, P = 0.045) and Killip IV (OR: 51.59, 95% CI: 2.65–1,005.30, P = 0.009).ConclusionThe history of diabetes, poor renal function and heart failure were associated with the high risk of GIB in patients experiencing AMI. The in-hospital mortality in patients with AMI complicating GIB was higher than that in patients without GIB and was associated with a decreased hemoglobin concentration and high Killip classification.

show abstract

Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease

Cited by 2 publications

References 0 publications

In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease

In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease

Clinical characteristics and risk factors of in-hospital gastrointestinal bleeding in patients with acute myocardial infarction

Contact Info

Product

Resources

About